MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$183K
Free Cash flow
$2,743K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Prepaid expenses and other asset...
    • Accounts receivable
    • Accrued and other liabilities
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable
    • Purchases of investments
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-13,494
5,179
55,045
-8,141
Depreciation and amortization
741
1,126
2,055
2,080
Loss on sale of property and equipment
8
-10
-33
-5
Net accretion of discounts on investments
84
56
71
42
Gain on modification of lease liability
-
-
1,005
-
Stock-based compensation
1,290
1,482
1,716
2,018
Change in fair value of equity-linked instrument
-341
-
-
-
Non-cash interest expense related to sale of future royalties
538
505
546
607
Non-cash revenue related to sale of future royalties
41
331
0
0
Accounts receivable
-7,128
-7,425
-28,152
38,435
Unbilled receivable from government contracts
-3,454
13,654
-6,448
6,448
Prepaid expenses and other assets
-7,326
-7,889
18,054
-417
Prepaid clinical services, long-term
-
-
-34,898
0
Accounts payable
-7,297
2,674
-31,579
42,570
Deferred revenue-Government Contract
39
-45
-64,760
-549
Deferred revenue-Collaboration Revenue
-2,919
-2,815
14,976
-
Other accrued liabilities
-
-
-
8,513
Accrued and other liabilities
5,764
-11,443
33,735
-
Net cash provided by (used in) operating activities
2,778
-2,054
30,663
2,595
Purchases of property and equipment
35
448
1
117
Proceeds from sale of property and equipment
10
3
0
5
Purchases of investments
5,571
10,231
4,010
9,410
Proceeds from maturities of investments
2,880
10,000
6,000
3,700
Net cash (used in) provided by investing activities
-2,716
-676
1,989
-5,822
Net proceeds from issuance of common stock-Ra Capital Healthcare Fund2025
-
-
4,201
-
Net proceeds from issuance of common stock-June2024Offering
-
-
0
0
Net proceeds from issuance of common stock through at-the-market facilities-Atthemarket Facility
0
-
0
0
Issuance cost of equity line of credit commitment shares
167
-
-
-
Net proceeds from issuance of common stock-RACapital Healthcare Fund2024
-
-
0
0
Net proceeds from issuance of common stock through at-the-market facilities-Equity Line Of Credit
44
-
-
-
Proceeds from issuance of common stock upon exercise of stock options
57
0
0
0
Shares acquired to settle employee tax withholding liabilities
26
338
21
4
Proceeds from issuance of common stock under the employee stock purchase plan
-
-
0
0
Proceeds from issuance of treasury stock under the employee stock purchase plan
213
-
102
0
Net cash used in financing activities
121
-338
4,282
-4
Net decrease in cash and cash equivalents
183
-3,068
36,934
-3,231
Cash and cash equivalents at beginning of the period
50,746
53,814
16,880
25,229
Cash and cash equivalents at end of the period
50,929
50,746
53,814
16,880
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Prepaid expenses andother assets-$7,326K (-377.57%↓ Y/Y)Proceeds from issuance oftreasury stock under the...$213K (169.62%↑ Y/Y)Accounts receivable-$7,128K (-381.62%↓ Y/Y)Accrued and otherliabilities$5,764K Unbilled receivable fromgovernment contracts-$3,454K (-111.30%↓ Y/Y)Stock-based compensation$1,290K (-71.83%↓ Y/Y)Depreciation andamortization$741K (-83.33%↓ Y/Y)Non-cash interestexpense related to sale...$538K (-67.78%↓ Y/Y)Change in fair value ofequity-linked instrument-$341K Deferredrevenue-Government Contract$39K (269.57%↑ Y/Y)Proceeds from issuance ofcommon stock upon...$57K (1800.00%↑ Y/Y)Net proceeds fromissuance of common stock...$44K Net cash provided by(used in) operating...$2,778K (110.88%↑ Y/Y)Net cash used infinancing activities$121K (410.26%↑ Y/Y)Canceled cashflow$23,843K Canceled cashflow$193K Net decrease in cashand cash...$183K (103.58%↑ Y/Y)Canceled cashflow$2,716K Net loss-$13,494K (55.87%↑ Y/Y)Accounts payable-$7,297K (-300.03%↓ Y/Y)Deferredrevenue-Collaboration Revenue-$2,919K Net accretion ofdiscounts on investments$84K (-49.09%↓ Y/Y)Non-cash revenue relatedto sale of future...$41K (-99.09%↓ Y/Y)Loss on sale ofproperty and equipment$8K Proceeds from maturitiesof investments$2,880K (-90.50%↓ Y/Y)Proceeds from sale ofproperty and equipment$10K Issuance cost of equityline of credit...$167K Shares acquired tosettle employee tax...$26K (-85.06%↓ Y/Y)Net cash (used in)provided by investing...-$2,716K (-113.27%↓ Y/Y)Canceled cashflow$2,890K Purchases of investments$5,571K (-43.20%↓ Y/Y)Purchases of property andequipment$35K (29.63%↑ Y/Y)

Vaxart, Inc. (VXRT)

Vaxart, Inc. (VXRT)